These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32579975)

  • 1. Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.
    Li Q; Chen Q; Klauser PC; Li M; Zheng F; Wang N; Li X; Zhang Q; Fu X; Wang Q; Xu Y; Wang L
    Cell; 2020 Jul; 182(1):85-97.e16. PubMed ID: 32579975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically Encoding Fluorosulfate-l-tyrosine To React with Lysine, Histidine, and Tyrosine via SuFEx in Proteins in Vivo.
    Wang N; Yang B; Fu C; Zhu H; Zheng F; Kobayashi T; Liu J; Li S; Ma C; Wang PG; Wang Q; Wang L
    J Am Chem Soc; 2018 Apr; 140(15):4995-4999. PubMed ID: 29601199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants.
    Yu B; Li S; Tabata T; Wang N; Cao L; Kumar GR; Sun W; Liu J; Ott M; Wang L
    Chem; 2022 Oct; 8(10):2766-2783. PubMed ID: 35874165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically encoding latent bioreactive amino acids and the development of covalent protein drugs.
    Wang N; Wang L
    Curr Opin Chem Biol; 2022 Feb; 66():102106. PubMed ID: 34968810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Genetically Encoded Fluorosulfonyloxybenzoyl-l-lysine for Expansive Covalent Bonding of Proteins via SuFEx Chemistry.
    Liu J; Cao L; Klauser PC; Cheng R; Berdan VY; Sun W; Wang N; Ghelichkhani F; Yu B; Rozovsky S; Wang L
    J Am Chem Soc; 2021 Jul; 143(27):10341-10351. PubMed ID: 34213894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity.
    Zhang B; Sun J; Yuan Y; Ji D; Sun Y; Liu Y; Li S; Zhu X; Wu X; Hu J; Xie Q; Wu L; Liu L; Cheng B; Zhang Y; Jiang L; Zhao L; Yu F; Song W; Wang M; Xu Y; Ma S; Fei Y; Zhang L; Zhou D; Zhang X
    Signal Transduct Target Ther; 2023 Jan; 8(1):28. PubMed ID: 36690610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New covalent bonding ability for proteins.
    Cao L; Wang L
    Protein Sci; 2022 Feb; 31(2):312-322. PubMed ID: 34761448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
    Ashizawa T; Iizuka A; Tanaka E; Kondou R; Miyata H; Maeda C; Sugino T; Yamaguchi K; Ando T; Ishikawa Y; Ito M; Akiyama Y
    Biomed Res; 2019; 40(6):243-250. PubMed ID: 31839668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerating PERx Reaction Enables Covalent Nanobodies for Potent Neutralization of SARS-Cov-2 and Variants.
    Yu B; Li S; Tabata T; Wang N; Kumar GR; Liu J; Ott MM; Wang L
    bioRxiv; 2022 Mar; ():. PubMed ID: 35313590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encoding latent SuFEx reactive meta-fluorosulfate tyrosine to expand covalent bonding of proteins.
    Klauser PC; Berdan VY; Cao L; Wang L
    Chem Commun (Camb); 2022 Jun; 58(48):6861-6864. PubMed ID: 35621237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biospecific Chemistry for Covalent Linking of Biomacromolecules.
    Cao L; Wang L
    Chem Rev; 2024 Jul; 124(13):8516-8549. PubMed ID: 38913432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
    Verdura S; Cuyàs E; Cortada E; Brunet J; Lopez-Bonet E; Martin-Castillo B; Bosch-Barrera J; Encinar JA; Menendez JA
    Aging (Albany NY); 2020 Jan; 12(1):8-34. PubMed ID: 31901900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
    Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P
    Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent peptides and proteins for therapeutics.
    Berdan VY; Klauser PC; Wang L
    Bioorg Med Chem; 2021 Jan; 29():115896. PubMed ID: 33285408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
    Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
    Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 20. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
    Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
    Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.